DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway

DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway

Diffuse large B cell lymphoma (DLBCL) is a clinical and genetically heterogeneous lymphoid malignancy. Although R-CHOP (rituximab plus cyclophosphamide, vincristine, doxorubicin, and prednisone) treatment can improve the survival rate of patients with DLBCL, more than 30% of patients exhibit treatme...

Full description

Bibliographic Details
Main Authors: Shuaikang Chang, Bo Li, Yongsheng Xie, Yingcong Wang, Zhijian Xu, Shuhan Jin, Dandan Yu, Huaping Wang, Yumeng Lu, Yong Zhang, Ruye Ma, Cheng Huang, Weiming Lai, Xiaosong Wu, Weiliang Zhu, Jumei Shi
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Diffuse large B cell lymphoma
DCZ0014
Apoptosis
Lyn
Syk
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558621001056

Internet

http://www.sciencedirect.com/science/article/pii/S1476558621001056

Similar Items